Stocks · News reference

RenovoRx shares are trading higher after the company announced the publication of pharmacokinetic and pharmacodynamic data from a sub-study of its ongoing Phase III TIGeR-PaC clinical trial in the journal Cancer Chemotherapy and Pharmacology.

Aug 25, 2026, 5:26 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 25, 2026, 5:06 PMBenzinga Insights
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Picard Medical (AMEX:PMI) shares moved upwards by 82.7% to $9.38 during Tuesday's regular session. The market value of their outstanding shares is at $10.5 million. As per the news, the Q2 earnings report
Read original at benzinga
AIXC AMIX CDT CELGR JUNS
BenzingaAug 25, 2026, 12:36 PMBenzinga Newsdesk
RenovoRx Announces Publication Of Sub-Study Data From Its Ongoing Phase III TIGeR-PaC Clinical Trial In The Journal Cancer Chemotherapy And Pharmacology; Data Show Trans-Arterial Micro-Perfusion-Mediated Delivery Concentrated Chemotherapy At The Tumor Site, Extracting ~51% Of Drug Locally Before It Entered The Bloodstream, Meaningfully Lowering Systemic Exposure
RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared
Read original at benzinga
RNXT
SEC EDGARAug 20, 2026, 8:05 PMSEC EDGAR
8-K filing — RenovoRx, Inc. (RNXT)
Filed: 2026-08-20 AccNo: 0001493152-26-039472 Size: 202 KB Item 8.01: Other Events
Read original at edgar
RNXT